A multi-center, un-controlled, open-labeled trial of the long-term safety of Lamazym aftercare treatment of subjects with alpha-Mannosidosis who previously participated in Lamazym-trials

Trial Profile

A multi-center, un-controlled, open-labeled trial of the long-term safety of Lamazym aftercare treatment of subjects with alpha-Mannosidosis who previously participated in Lamazym-trials

Active, no longer recruiting
Phase of Trial: Phase III

Latest Information Update: 10 Feb 2017

At a glance

  • Drugs Velmanase alfa (Primary)
  • Indications Alpha-Mannosidosis
  • Focus Adverse reactions; Therapeutic Use
  • Sponsors Zymenex A/S
  • Most Recent Events

    • 01 Sep 2016 Planned End Date changed from 1 Feb 2017 to 1 Dec 2018.
    • 01 Sep 2016 Planned primary completion date changed from 1 Dec 2016 to 1 Dec 2018.
    • 10 Jun 2015 Status changed from recruiting to active, no longer recruiting, as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top